AGA Center for Diagnostics & Therapeutics

Drug development is a complex, time-consuming and expensive process requiring the cooperation of various stakeholders. To help facilitate this process, the AGA Center for Diagnostics and Therapeutics provides objective, independent guidance to companies, regulators, investors and health-care professionals on the development of new therapies and diagnostic tests for digestive disorders.

Expertise and Opportunities

• Identification of Experts and Organization of Expert Meetings

• Clinical Study Design and Endpoint Development

• Development of Educational Programs and Resources

We invite AGA partners to suggest other issues facing the drug and diagnostic industries related to clinical development and regulatory approval.


GERD White Paper

White paper provides recommendations for clinical trial design and end points for GERD. This white paper was developed based on presentations from the AGA Drug Development Conference.

EoE White Paper

White paper provides recommendations for industry working on development of pharmacologic therapies in eosinophilic esophagitis (EoE). This resource is a result of the 2016 AGA Drug Development Conference.

Functional Dyspepsia White Paper

In this white paper, experts discuss the current status of drug development, progress with a validated patient reported outcome instrument in functional dyspepsia, future directions and needs.

Gastroparesis White Paper

White paper provides clinical and regulatory insights for clinical trials in gastroparesis. Developed from the AGA Drug Development Conference.

FDA Comment Letter

The AGA Center for Diagnostics and Therapeutics submitted comments on FDA’s 2015 draft guidance document entitled “Gastroparesis: Clinical Evaluation of Drugs for Treatment.”

Introduction to the Center

Learn more about why the center was established and its work in the drug and diagnostic space in this AGA Perspectives editorial by Dr. Colin Howden.

Scientific Advisory Board

Colin W. Howden, MD, AGAF, Chair

Colin W. Howden, MD, AGAF, Chair

University of Tennessee Health Science Center, Memphis

Tara A. Altepeter, MD, FDA Liaison*

Food and Drug Administration, Silver Spring, MD

J. Summer Bell III, MD, AGAF

Gastroenterology Ltd., Virginia Beach, VA

Glenn T. Furuta, MD

Children’s Hospital Colorado, Aurora

M. Scott Harris, MD, AGAF

Avaxia Biologics and Georgetown University, Washington, DC

Rajeev Jain, MD, AGAF, Governing Board Liaison

Texas Digestive Disease Consultants, Dallas

Loren Laine, MD, AGAF

Yale University School of Medicine, Fairfield, CT

Gary R. Lichtenstein, MD, AGAF

University of Pennsylvania, Philadelphia

Fred Poordad, MD

University of Texas Health Science Center, San Antonio

Debra G. Silberg, MD, PhD

Shire Pharmaceuticals, Wayne, PA

Nimish B. Vakil, MD, AGAF

University of Wisconsin Medical School, Summit, WI

Teresa L. Wright, MD, AGAF

Genentech, San Francisco, CA

*Denotes non-voting member.

Are you ready to take the next step?

To learn more about the center, please contact Alison Kim, senior director of research and innovation.

Phone Icon


Pin Icon

4930 Del Ray Ave.
Bethesda, MD 20814

Stay Connected